ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES USE OF MULTI-CRITERIA DECISION ANALYSIS TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning entitled, The Potential and Pitfalls of Using Multi-Criteria Decision Analysis to Support Health Technology Assessment. The session took place at the Society’s 19th Annual European Congress in Vienna, Austria. The workshop was led by discussion leaders that included:
  • Janine A. van Til, PhD, Assistant Professor Preference Research, Health Technology and Services Research, University of Twente, Enschede, The Netherlands
  • Rob Baltussen, PhD, Associate Professor Health Economics, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
  • Michele Tringali, MD, Director, HTA Program, Lombardy Region Health Directorate, Milan, Italy
  • Susanne Schmitz, PhD, Postdoctoral Fellow, Department of Population Health/Health Economics and Evidence Synthesis Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg
The workshop reviewed a number of practical examples to illustrate how health technology assessment (HTA) and reimbursement decisions can be supported with multi-criteria decision analysis (MCDA). The panelists discussed the apparent fit between MCDA and HTA decision making and reviewed the use of a deliberative approach to MCDA that involves stakeholder consultation. Case studies from the Netherlands, Thailand, and Indonesia were presented and results of a retrospective analysis demonstrated potentially important drivers of reimbursement decisions in Ireland and outlined the challenges of using such information to inform an actual MCDA framework. A number of knowledge products on MCDA have been developed by ISPOR’s Multi-Criteria Decision Analysis in Health Care Decision Making Task Force, including the following Task Force Reports published in Value in Health: Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×